Poly Medicure growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.3%+21.4%+23.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−2.3%+26.4%+35.0%
−11.7%+25.8%+41.3%
−5.3%+31.1%+44.1%
−6.9%+26.8%+44.0%
+22.7%+71.8%+17.8%
+13.9%+88.1%+18.4%
−0.2%−9.4%+39.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

POLYMED₹1,461.90

Poly Medicure Ltd.

· Pharma & Health
₹ CrorePeersPFIZERRAINBOWONESOURCEKIMSJUBLPHARMAVIJAYAINDGNGRANULESMcap ₹14,818 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+23.4+21.4+12.3—
EBITDA Growth—+35.0+26.4-2.3—
EBIT Growth—+41.3+25.8-11.7—
Net Income Growth—+44.1+31.1-5.3—
EPS Growth—+44.0+26.8-6.9—
Total Assets Growth—+17.8+71.8+22.7—
Total Equity Growth—+18.4+88.1+13.9—
Cash from Operations Growth—+39.4-9.4-0.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.